SandboxAQ today announced a technology collaboration with Mayo Clinic to explore the use of advanced, AI-powered magnetocardiography (MCG) technology with the goal of radically improving cardiac diagnostics. The collaboration marks a significant step forward in the global fight against cardiovascular diseases, which remain one of the leading causes of death worldwide, claiming millions of lives every year.

As part of the collaboration, Mayo Clinic researchers will test SandboxAQ’s novel MCG imaging system, called CardiAQ, powered by state-of-the-art magnetic sensors and advanced AI algorithms. This mobile, non-invasive, non-contact cardiac imaging device will enable rapid and radiation-free visualization and assessment of the magnetic signals of the heart. The initial phase of the collaboration will be a clinical research study to examine the relationship between MCG and the findings seen in angiography. The study will take place throughout 2024 and 2025 at the Mayo Clinic in Rochester, MN.

“This collaboration between Mayo Clinic and SandboxAQ will further this breakthrough MCG technology for cardiac diagnostics.  Cardiac disease is the leading cause of death globally and novel methods to easily and accurately diagnose disease are urgently needed,” said Kit Yee Au-Yeung, Director of SandboxAQ’s medical devices division. “CardiAQ captures detailed data from the heart, which could lead to faster, more accurate diagnoses and fill in the gap between low-cost EKG or biomarker tests and high-cost CT scans or invasive angiography.”

CardiAQ will look to address the need for faster, more accurate and accessible medical imaging technologies. The system leverages high performance sensors to measure minute variations in the magnetic field around the human heart, and advanced quantitative AI algorithms that can eliminate electromagnetic interference in a dynamic hospital environment. By capturing more pristine electrical conduction activities in every heartbeat, doctors may be able to better detect abnormal patterns and uncover other indicators about potential cardiac disease states.

Building upon successful clinical studies at UCSF Medical Center and New York’s Mount Sinai West medical center, CardiAQ delivers key benefits including:

• Requires no purpose-built space
• Mobile for point-of-care use
• Requires no cooling or shielding to operate
• Measurement takes minutes to complete

For more information about SandboxAQ’s MCG device, please visit https://www.sandboxaq.com/sensing

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post SandboxAQ Collaborates with Mayo Clinic on Novel Cardiac Diagnostics first appeared on AI-Tech Park.

Zscale Labs is excited to announce the launch of its revolutionary Neuromorphic AI, a state-of-the-art tool designed to advance medical diagnostics by enabling multi-label Chest X-Ray image classification. This breakthrough technology demonstrates how Zscale Labs is reshaping the landscape of healthcare through cognitive computing.

Accurate and timely diagnosis is critical, particularly for respiratory conditions. Our innovative tool leverages the power of Zscale Labs Hyperdimensional Computing (HDC) and deep learning to assist radiologists and healthcare providers in diagnosing multiple chest conditions from X-ray images. This ensures better patient outcomes and underscores the transformative potential of AI in precision medicine.

Key features of our Neuromorphic AI breakthrough include:

• Advanced Spatial Transformer Network (STN): Enhances the precision of image analysis by focusing on relevant areas within X-rays.
• Hyperdimensional Computing (HDC) Encoding: Operates in a high-dimensional space for superior pattern recognition and accurate multi-label classification.

Zscale Labs brain-inspired approach empowers medical professionals with intricate details crucial for precise diagnosis, operating efficiently in high-dimensional spaces to enhance pattern cognition. This technology not only improves diagnostic accuracy but also significantly reduces analysis time, making it an invaluable tool in modern healthcare.

For more information about Zscale Labs and its Neuromorphic AI technology, visit
https://www.zscalelabs.com/post/revolutionizing-healthcare-with-neuromorphic-ai

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Zscale Labs™ Unveils Groundbreaking Neuromorphic AI for Medical Imaging first appeared on AI-Tech Park.

Akyuz brings extensive leadership experience in healthcare and imaging technology, having served as President and CEO at major healthcare and medical systems companies including Rhapsody, Change Healthcare and Toshiba Medical Systems, where, under his leadership, the companies experienced improved profitability, customer retention and growth. Recognized for his ability to transform business models, Akyuz combines his technological background with his strategic prowess to drive operational excellence.

“I have long admired Circle and its role at the forefront of the medical imaging industry, offering best-in-class AI-powered solutions to hospitals, physicians and patients on a global scale,” said Erkan Akyuz. “I am thrilled to be joining this impressive team and look forward to leading Circle as we continue to advance our mission of improving patient outcomes worldwide.”

Akyuz is joining Circle, the leading provider of AI-based cardiac imaging and reporting solutions, during a period of accelerated growth and product innovation. Since Thoma Bravo’s investment in Circle in April 2022, the Company has expanded its global footprint from approximately 50 countries to over 90 countries and has continued to innovate on its cutting-edge AI-driven solutions. Earlier this year, Circle launched its next generation platform, cvi42 6.1, which is centered around growing with the medical field with a focus on accessibility, interoperability and efficiency.

“On behalf of the Thoma Bravo team, I want to thank Greg for his unwavering leadership and commitment to innovation that led Circle to become the category leader that it is today,” said Carl Press, a Partner at Thoma Bravo. “Under Greg’s stewardship, Circle transformed from a university-led research project into a market leading diagnostic platform that has benefitted tens of thousands of cardiology patients globally. We are humbled by the impact that he has made in the world of medical imaging and are truly grateful for our partnership with him. At the same time, we are thrilled to welcome Erkan to Circle and look forward to working closely together as we build on a strong foundation and continue to drive product innovation and growth globally.”

“It has been a privilege to lead the dedicated and passionate team at Circle, and I am proud of what we have achieved together,” said Greg Ogrodnick. “I’m confident that Erkan is the right person to lead Circle in the next phase of its journey, and I look forward to watching the Company’s continued success.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Circle Cardiovascular Imaging Announces Leadership Transition first appeared on AI-Tech Park.

Avicenna.AI, a leading medical imaging AI company, has received Medical Device Regulation (MDR) certificate for five of its algorithms from certification body BSI Medical Devices. This development means the company’s product portfolio is fully compliant with the European Union’s MDR 2017/745, which is now mandatory for medical device companies that want to provide their solutions in Europe.

The MDR was introduced to update the EU’s regulations for medical devices, addressing safety issues and the recent emergence of AI tools and software as a medical device (SaMD), which did not exist when the old regulations were created. Ensuring MDR compliance is a critical component of obtaining and maintaining CE-mark status, which allows a device to be freely traded in the EU.

Compared to the previous Medical Device Directive (MDD), the MDR has a wider scope and more stringent requirements. It emphasizes clinical evaluation, post-market surveillance, device traceability, rigorous technical documentation, and risk management. These measures aim to enhance patient safety and ensure high standards for medical devices, including AI and software-based solutions.

Avicenna.AI’s products have been certified as Class IIb medical devices, which requires a high level of clinical validation. The certified products include the company’s suite of AI tools for neurovascular conditions, as well as its suite of algorithms for vascular conditions.

“Obtaining MDR certification is a significant milestone for Avicenna.AI,” said Stéphane Berger, Regulatory Manager at Avicenna.AI. “It demonstrates our commitment to meeting the highest standards of medical device safety and performance. This certification not only reinforces our dedication to compliance but also assures our customers of the quality and reliability of our AI product portfolio.”

The company’s MDR-certified AI tools include algorithms for intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), quantification of stroke severity (CINA-ASPECTS), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE), and opportunistic cases of pulmonary embolism (CINA-iPE). All the products are also CE-marked and FDA-cleared.

“Crucially, despite the differences in SaMD regulatory requirements between authorities in the US and Europe, we are consistently achieving both FDA and CE mark clearance for our AI products,” added Berger.

All of Avicenna.AI’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Avicenna.AI secures MDR certification for medical imaging AI portfolio first appeared on AI-Tech Park.

Azra AI, a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer. Marshall will succeed Chris Cashwell, who will continue to support Azra as an advisor. With more than 25 years of experience in technology and healthcare, Marshall brings deep expertise in market-leading strategies and first-to-market technologies to drive Azra AI’s growth in response to rising market demand.

Marshall, a visionary executive and accomplished sales leader, has a remarkable history of expanding domestic and global market channels through dynamic sales strategies, focused P&L discipline, driving product innovation, and unique team-building techniques. His leadership has guided several companies to the forefront of medical imaging, data management, and health IT.

“Given the increasing demand for AI-driven healthcare solutions, John Marshall is the ideal leader to propel Azra AI to new heights. His extensive expertise in both technology and healthcare, along with a proven track record of leadership, makes him uniquely qualified to steer the company through this exciting growth phase,” said Abinav Sankar, Chairman of the Board at Azra AI and partner at Sopris Capital. “I also want to express my gratitude to Chris Cashwell for his exceptional work in positioning Azra AI as a healthtech leader and setting the stage for a promising future.”

Marshall has a proven track record of bringing first-of-its-kind technologies to market, impacting healthcare systems, IDNs, diagnostic reading groups, pharma, and contract research organizations worldwide. His sales and executive leadership abilities include developing strategic sales and product plans, as well as recruiting dynamic teams that lead markets with best-of-breed partners and channel management.

Prior to joining Azra AI, John Marshall served as Chief Operating Officer at Enlitic, Inc., where he guided the company to a successful IPO in December 2023, starting from zero revenue and building global sales and marketing teams. As Global VP of Sales at Client Outlook, he was able to globally commercialize their technology to the point of an all-cash acquisition by Mach7 Technologies in 2020. Marshall’s leadership as Global VP of Sales at Calgary Scientific turned a start-up with no revenue or sales teams, into a multimillion-dollar global software provider.

“I’m excited to join the talented team at Azra AI and contribute to a mission that aligns so closely with my passion for leveraging technology to make a real difference in healthcare. Automatically identifying, classifying, and abstracting cancer diagnoses and incidental findings from pathology and radiology reports makes an enormously positive impact not only for oncology operations, but for patients and their ability to know about their cancer earlier, thus giving them a chance to survive and beat cancer. Together, we’ll push the boundaries of innovation at Azra, ensuring that our solutions continue to empower hospitals and cancer centers to provide the best care possible while enhancing operational efficiency, deep clinical outcomes, and capitalizing on real ROI. I could not be more excited and thankful for this opportunity,” said Marshall.

Azra AI’s enterprise SaaS platform revolutionizes oncology care with advanced AI-driven automation that transforms workflows, improves cancer navigation, and empowers healthcare providers to act swiftly on positive cancer diagnoses and suspicious incidental findings. With John Marshall’s strategic leadership and focus on expanding the platform’s innovative capabilities, Azra AI will continue to drive impactful improvements in operational efficiency, patient care, and service line growth across the healthcare industry.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Azra AI Appoints John Marshall as New CEO first appeared on AI-Tech Park.

United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technology, boasting incredible advancements across various fronts, as a Gold sponsor at this year’s ISMRM meeting.

The company’s exhibit at this year’s ISMRM meeting strategically divides into four sections: Ultra-High Field, Ultra-High Gradient, Artificial Intelligence, and Innovation Community. Each section addresses industry priorities and showcases sophisticated technological advancements.

“United Imaging has always been dedicated to pushing boundaries and driving innovation,” says Dr. Al Zhang, Ph.D, Chairman & Co-CEO. “ISMRM holds immense value for us, fostering connections with global partners who share our drive for progress. Our purposeful innovation drives scientific research forward, leading to groundbreaking advancements in healthcare technology. Guided by our mission, ‘Equal Healthcare for All,’ we remain committed to pioneering solutions that enhance patient care worldwide.”

At the forefront of the “Ultra-High Field” showcase is the uMR Jupiter 5T, a revolutionary whole-body 5T MRI system that recently received FDA clearance. It transcends the traditional constraints of ultra-high-field MRI, previously confined to imaging of the brain and selected MSK joints. The potential applications of the uMR Jupiter 5T extend to encompass the abdomen, heart, pelvis, and additional anatomical regions. uMR Jupiter has the potential to eclipse the capabilities of standard 3T MRI machines in resolution and signal-to-noise ratio, delivering clarity that empowers radiologists to uncover clinical details previously hidden, truly allowing them to ‘see the unseen.’ The uMR Jupiter 5T is also designed to overcome the key hurdles of ultra-high-field MRI: image uniformity and radio frequency safety. It fits into existing 3T MRI spaces, signaling a significant advancement in the industry.

Highlighted also in the “Ultra-High-Field” section is the “SuperFlexFree Coils” (not available in the U.S. or EU for commercial or clinical use). There are three types of coils in this set and all are 24 channels. Each is designed for scanning large joints and the heart, small joints, and delicate structures respectively. Compared to traditional coils, SuperFlexFree Coils have a significantly higher coil density and flexibility, which will result in better image signal-to-noise ratio and acceleration performance.

Additionally, United Imaging introduces breakthroughs in the “Ultra High Gradient” category, including the uMR Sagitta (not submitted to the FDA; not available in the U.S. for commercial or clinical use) and the uMR NX Frontier (not submitted to the FDA; not available in the U.S. for commercial or clinical use). uMR Sagitta completely revolutionizes the performance limits of magnetic resonance, achieving significant advances in global research in 3T systems. With the powerful ‘Twin-Engine technology’ driving force, its gradient performance surpasses 240 mT/m and 200 T/m/s, offering a fresh perspective in precise diagnosis and treatment. uMR NX Frontier (not submitted to the FDA; not available in the U.S. for commercial or clinical use), dedicated to brain research, serves as the new-gen model of Human Connectome Project (HCP) studies, boasting ultra-high-performance gradients of 650 mT/m and 600 T/m/s, leading a frontier exploration in neuroscience.

For the “Artificial Intelligence” section, United Imaging highlights the uAIFI Technology Platform, an innovative end-to-end technology platform that revolutionizes MRI through AI-integrated hardware and software. It significantly enhances image quality, expedites diagnostic processes and improves user-friendliness, pioneering advances in patient care. This holistic approach spans the care continuum, with standout features like ACS, an AI-assisted MR acceleration technology for enhanced 2D and 3D imaging. This platform evolved intelligently, bringing a new level of AI integration to uMR systems.

United Imaging has always been dedicated to advancing MRI research through collaboration with industry partners. The ADEPT platform – Application Developing Environment and Programming Tools — is a comprehensive platform offering essential features of precise hardware control and effortless application development. Coupled with extensive support for research platform interfacing and a vibrant scientific community, ADEPT marks a significant leap forward in accelerating user development and advancing scientific research in the field of MRI.

ISMRM attendees are invited to experience the future of MRI at Booth A18.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post United Imaging to unveil latest MRI Advancements at ISMRM 2024 first appeared on AI-Tech Park.

PocketHealth, the leader in patient-centric medical image exchange, today announced it has raised $33 million USD ($45 million CAD) in Series B funding. The all-equity round was led by Round13 Capital with participation from Deloitte Ventures, Samsung Next, and existing investors Questa Capital and Radical Ventures.

The funding will enable PocketHealth to continue to evolve how medical images are shared, leverage AI to personalize the patient’s care journey, and grow its footprint across the US and Canada. To support these goals, the company plans to double its workforce over the next two years.

PocketHealth was founded in 2016 by brothers Harsh and Rishi Nayyar to give patients access, control, and a deeper understanding of their health records while streamlining the way healthcare providers share medical imaging.

“Medical imaging is the spark to nearly every patient journey, yet manual and legacy image sharing systems deemphasize patient access to their own data, generating unnecessary costs, and delaying patient care,” said Rishi Nayyar, Co-Founder and CEO, PocketHealth. “We’ve proven that when patients gain access to diagnostic-quality imaging and our industry-leading AI helps them understand their records, they are empowered to advocate for their care. The end result is increased patient satisfaction, a faster image sharing process for providers, and greater patient retention. Now, our goal is to make PocketHealth accessible to every patient at every provider across North America.”

With PocketHealth, providers gain a secure, next-generation platform for easily exchanging diagnostic images with both patients and external providers. Uniquely, PocketHealth customers have the flexibility to instantly share images with anyone, across any network — or set up a local network of PocketHealth Community Gateways for automated image exchange. This ensures that records get where they need to, instead of relying on a CD-ROM, return visits to the hospital, or a broken portal experience, which disrupts the patient’s care journey.

The platform uses AI to provide patients with personalized insights and improved understanding of their health. Report Reader explains medical terms in the patient’s report, Follow-Up Navigator intelligently detects follow-up imaging recommendations — encouraging patients to return for new imaging on-schedule — and MyCare Navigator equips patients with relevant, personalized questions to ask their doctor. As a result, 87% of patients surveyed say they are more likely to return to the same healthcare provider when they have access to their imaging through PocketHealth.

“For 20 years, medical image exchange has meant moving files across a closed network, from point A to point B,” said Nayyar. “We’re now seeing some of the largest health systems in North America expecting more from their image exchange and adopting PocketHealth to drive patient retention, satisfaction, and finally solve their image exchange needs.”

PocketHealth connected sites have seen improved patient experience, operational efficiencies, and cost savings.

• Colorado’s Valley View Hospital reduced non-labor costs associated with burning CDs by 95% and enabled patient and staff image sharing with out-of-network providers.
• Toronto’s Unity Health gained more than $120,000 in annual savings and closed their imaging library.

“PocketHealth is tackling a massive problem that requires the ability to build a thoughtful, resilient product experience for patients, physicians, and the most complex healthcare providers,” said Brahm Klar, Managing Partner, Round13 Capital. “We are impressed with how effectively the PocketHealth team has been able to rise to this challenge and create a solution that ensures data gets where it needs to go, instantly, empowering patients along the way. We are thrilled to join PocketHealth on this journey, and look forward to this exciting next stage of growth.”

Over its eight-year journey, PocketHealth has secured contracts with major health systems and outpatient imaging groups across North America including University Health Network, Southern Illinois Healthcare, UofL Health, Universal Health Services, Radiology Partners, and more. With this funding, the company has raised over $55.5 million USD ($75 million CAD) in equity to date. Miranda Ferris, Principal at Round13 Capital, will join the PocketHealth Board.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post PocketHealth raises $33M USD in Series B Funding first appeared on AI-Tech Park.

Coreline Soft, a pioneer in medical artificial intelligence (AI) imaging, unveils cutting-edge AI medical imaging solutions at the ECR 2024 (European Congress of Radiology), establishing a new standard for healthcare across Europe. ECR, the largest radiology conference in Europe, attracts global experts and medical device industry professionals.

Coreline Soft is set to make a mark at the ECR 2024 by presenting its AVIEW product line. The exhibition will feature demonstrations of AVIEW LCS Plus for simultaneous diagnosis of chest diseases, AVIEW COPD for automatic analysis of chronic obstructive pulmonary disease, and AVIEW RT ACS, an AI-based fully automated contouring solution.

The showcase will encompass a comprehensive range of products from screening and diagnosis to treatment and management. Highlighting the AVIEW LCS Plus, capable of screening three major pulmonary conditions in CT scans, the presentation will focus on real-world applications in hospitals worldwide. The company will share insights into the benefits for medical professionals, workflow improvements, and enhanced diagnostic efficiency.

Coreline Soft has been actively expanding its presence in Europe, securing projects such as the multinational lung cancer screening initiative (iDNA) involving five European countries. Projects like the HANSE lung cancer screening in Germany and the ILSP lung cancer screening in Italy, led by the prestigious National Cancer Institute in Milan with 18 participating hospitals and cancer centers, showcase the company’s competitiveness in the global lung cancer screening market.

Having recently signed supply agreements with renowned institutions such as Heidelberg University Hospital in Germany, Catania University Hospital in Italy, and the large imaging center group ImaGen in France, Coreline Soft is poised to further extend its footprint in the European healthcare market.

Jason Seo, Director of Overseas Business Development at Coreline Soft, said, “We have accumulated expertise in entering local hospitals and national-level projects, positioning the European market as a forward base for the global market.”

Coreline Soft continues to strengthen its global presence, offering innovative AI solutions to advance healthcare practices in Europe and beyond.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

The post Coreline Soft unveils AI medical imaging solutions at ECR 2024 first appeared on AI-Tech Park.

To read the US and global reports, visit: 
https://klasresearch.com/report/2024-best-in-klas-awards-software-and-services/3413
https://klasresearch.com/report/2024-best-in-klas-awards-global-software/3414

“These awards showcase our excellent employees who continuously go above and beyond to meet customer needs. Over the past year, we have restructured our organization into teams to ensure consistent and knowledgeable guidance throughout the sales, implementation, and support phases of the customer journey. This, along with product offerings that reduce IT costs, increase security, and grow with our users’ enterprise imaging requirements, has solidified our success,” says Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions.

Sectra 2024 Best in KLAS honors include US Large PACS, US Small PACS, PACS Global (Canada), PACS Global (Northern Europe), and PACS Global (Southern Europe). 

The first Sectra PACS installation was in Sweden in 1993, and now, the company has more than 2,500 sites worldwide. The radiology module is an integral part of Sectra’s enterprise imaging solution, also comprising VNA and imaging modules for cardiology, orthopedics, ophthalmology, and digital pathology in one single system.

Adam Gale, CEO of KLAS shared his thoughts for the 2024 winners:
“At KLAS, we firmly believe that the voice of healthcare providers and payers is paramount. The Best in KLAS awards are based on extensive feedback and evaluations from healthcare professionals across the nation. Winning a Best in KLAS award, therefore, is not just about recognition; it shows the trust and confidence that healthcare providers place in the winning vendors. It also helps validate each vendor’s commitment to innovation, quality, and customer satisfaction. We are proud to recognize 2024’s Best in KLAS award winners! Their unwavering dedication to improving patient outcomes is wonderfully inspiring.” 

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

The post Sectra won 5 Best in KLAS awards in 2024 first appeared on AI-Tech Park.

Intelerad Medical Systems, a global leader in medical imaging software solutions, was recognized as a 2024 Best in KLAS: Global Software Report award winner. The company has earned its recognition as the 2024 Best in KLAS vendor for the UK and Ireland PACS, leading the category across both regions based on provider and payers’ feedback in 2023.

Intelerad’s InSight PACS is a tailor-made PACS solution that has been adopted by over 250 healthcare providers across the UK and Ireland. The technology features a single, powerful interface for all users, and offers advanced functionality that delivers key clinical benefits such as advanced regional image sharing and MDT support, home reporting and teleradiology, and seamless integration with AI algorithms. The innovative PACS offering is a critical resource for UK healthcare professionals, who are facing an ageing and growing population, and a shortage of radiologists in addition to challenges around costs of healthcare.

“The demand for better technology that can drive essential workflow efficiencies for healthcare providers and help solve industry issues is greater than ever. Intelerad’s InSight PACS is a solution that is built and refined by UK professionals for UK clinicians who understand the needs and challenges standing in the way of better care outcomes,” said Morris Panner, President, Intelerad. “Receiving this recognition by KLAS as the number one leader in UK and Ireland PACS for 2024 is an incredible honour, and we will continue investing in this critical technology to better serve healthcare providers and the patients they serve.”

As the most comprehensive report of its kind in the healthcare IT industry, the annual 2024 Best in KLAS: Global Software Report recognizes vendors for their outstanding efforts to help healthcare professionals deliver better patient care. Using KLAS’ research process and methodology, all rankings are a direct result of the feedback from thousands of providers over the last year. A Best in KLAS award determines the standard of excellence that the top vendors should provide in a partnership.

“At KLAS, we firmly believe that the voice of healthcare providers and payers is paramount. The Best in KLAS awards are based on extensive feedback and evaluations from healthcare professionals across the nation. Winning a Best in KLAS award, therefore, is not just about recognition; it shows the trust and confidence that healthcare providers place in the winning vendors,” said Adam Gale, CEO, KLAS Research. “It also helps validate each vendor’s commitment to innovation, quality, and customer satisfaction. We are proud to recognize 2024’s Best in KLAS award winners! Their unwavering dedication to improving patient outcomes is wonderfully inspiring.”

A sample of feedback from the providers who use Intelerad’s InSight PACS and participated* in the KLAS research process is included below.

“The vendor has good customer support in the UK. The product is reliable with very few, if any, unplanned instances of downtime. The product is easy to use.” – Manager, September 2023

“The vendor’s biggest strengths and the things we like most are the desktop support and the trainer knowledge and that the network team is all very knowledgeable. InSight PACS and our other PACS work well together and are reliable. The Intelerad system is adequate for breast screening images, and it manages tomosynthesis images well and is easy to use. The consultants are happy with the product when reading images.” – Manager, September 2023

“InSight PACS Is a user-friendly product, and the vendor has an excellent support team for when something isn’t working properly.” – Manager, September 2023
*Selected commentary collected about Intelerad’s InSight PACS © 2023 KLAS. Visit klasresearch.com for a complete view.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

The post Intelerad’s InSight PACS awarded Best in KLAS for UK and Ireland PACS first appeared on AI-Tech Park.